Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SPLP gene therapies - Protiva

Drug Profile

Research programme: SPLP gene therapies - Protiva

Alternative Names: Pro-101; Pro-41; Pro-Alpha; Pro-Beta; SPLP gene therapy research programme - Protiva

Latest Information Update: 18 May 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protiva Biotherapeutics
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 May 2009 Discontinued - Preclinical for Cancer in Canada (IV)
  • 17 Jun 2003 Pro 1 has advanced from this research programme into clinical development
  • 07 Feb 2001 Preclinical trials for Inflammation in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top